Jon, thanks for the detailed post from an obvious supporter of the business. I was an interested observer of Bioxyne and although this was a balls-up of monumental proportion, I can't agree with your interpretation of events there, and some assertions you make are factually incorrect imo.
I can't predict if Radford will be the saviour of THC, but I feel pretty sure his experience in running medical products companies is what this business needs. As you say 'Of course it's nice to see the share hit 30.5c today but it should have been much more than this to begin with'. This sums up the markets conviction in the prior management.
- Forums
- ASX - By Stock
- EPN
- THC Management Revisited Mark II
EPN
epsilon healthcare limited
Add to My Watchlist
0.00%
!
2.4¢

THC Management Revisited Mark II, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.288M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
EPN (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online